207_Combined course Presentations

 PORT may be considered for fit patients with completely resected NSCLC with N2 nodal involvement , preferably after completion of adjuvant chemotherapy. This may reduce local recurrences ( 25-30% gain ), although no survival benefit has been demonstrated [III, B]

 A randomised clinical trial to assess the effect on survival is ongoing (LUNGART, NCT00410683)

 PORT can be indicated in case of a R1 or R2 resection , although survival in these patients remains poor [III, B]

Vansteenkiste J, et al. Ann Oncol. 2013;24